![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: DUSP8 |
Gene summary for DUSP8 |
![]() |
Gene information | Species | Human | Gene symbol | DUSP8 | Gene ID | 1850 |
Gene name | dual specificity phosphatase 8 | |
Gene Alias | C11orf81 | |
Cytomap | 11p15.5 | |
Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q13202 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
1850 | DUSP8 | PTC01 | Human | Thyroid | PTC | 5.67e-05 | 1.18e-01 | 0.1899 |
1850 | DUSP8 | PTC03 | Human | Thyroid | PTC | 7.63e-04 | 2.59e-01 | 0.1784 |
1850 | DUSP8 | PTC04 | Human | Thyroid | PTC | 5.45e-11 | 2.91e-01 | 0.1927 |
1850 | DUSP8 | PTC05 | Human | Thyroid | PTC | 5.48e-16 | 6.36e-01 | 0.2065 |
1850 | DUSP8 | PTC06 | Human | Thyroid | PTC | 3.45e-17 | 5.16e-01 | 0.2057 |
1850 | DUSP8 | PTC07 | Human | Thyroid | PTC | 6.38e-17 | 3.13e-01 | 0.2044 |
1850 | DUSP8 | ATC13 | Human | Thyroid | ATC | 2.76e-08 | 2.07e-01 | 0.34 |
1850 | DUSP8 | ATC5 | Human | Thyroid | ATC | 2.12e-13 | 2.38e-01 | 0.34 |
Page: 1 |
![]() |
Tissue | Expression Dynamics | Abbreviation |
Thyroid | ![]() | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis | ||
PTC: Papillary thyroid cancer |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Breast | Precancer | ![]() |
Breast | IDC | ![]() |
Breast | DCIS | ![]() |
Cervix | CC | ![]() |
Cervix | HSIL_HPV | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:001631116 | Thyroid | PTC | dephosphorylation | 174/5968 | 417/18723 | 1.20e-05 | 1.31e-04 | 174 |
GO:0043409112 | Thyroid | PTC | negative regulation of MAPK cascade | 76/5968 | 180/18723 | 2.15e-03 | 1.14e-02 | 76 |
GO:001631117 | Thyroid | ATC | dephosphorylation | 179/6293 | 417/18723 | 3.88e-05 | 3.15e-04 | 179 |
GO:004340926 | Thyroid | ATC | negative regulation of MAPK cascade | 82/6293 | 180/18723 | 5.51e-04 | 3.19e-03 | 82 |
Page: 1 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
DUSP8 | SNV | Missense_Mutation | novel | c.568G>A | p.Val190Ile | p.V190I | Q13202 | protein_coding | deleterious(0) | possibly_damaging(0.532) | TCGA-D8-A73U-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
DUSP8 | SNV | Missense_Mutation | novel | c.1690G>A | p.Ala564Thr | p.A564T | Q13202 | protein_coding | tolerated(0.23) | benign(0.047) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
DUSP8 | SNV | Missense_Mutation | novel | c.602N>G | p.Asp201Gly | p.D201G | Q13202 | protein_coding | deleterious(0.02) | benign(0.034) | TCGA-AA-3522-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
DUSP8 | SNV | Missense_Mutation | c.256N>A | p.Val86Met | p.V86M | Q13202 | protein_coding | deleterious(0) | possibly_damaging(0.752) | TCGA-AA-3663-01 | Colorectum | colon adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD | |
DUSP8 | SNV | Missense_Mutation | c.617G>A | p.Ser206Asn | p.S206N | Q13202 | protein_coding | tolerated(0.06) | benign(0.142) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
DUSP8 | SNV | Missense_Mutation | rs757458616 | c.98G>A | p.Arg33His | p.R33H | Q13202 | protein_coding | deleterious(0.02) | probably_damaging(0.97) | TCGA-CK-4951-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | PD |
DUSP8 | SNV | Missense_Mutation | c.913G>A | p.Ala305Thr | p.A305T | Q13202 | protein_coding | tolerated(0.18) | possibly_damaging(0.647) | TCGA-CM-4744-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
DUSP8 | SNV | Missense_Mutation | c.308G>A | p.Ser103Asn | p.S103N | Q13202 | protein_coding | tolerated(0.19) | benign(0.1) | TCGA-CM-5861-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
DUSP8 | SNV | Missense_Mutation | novel | c.280C>T | p.Arg94Trp | p.R94W | Q13202 | protein_coding | deleterious(0) | benign(0.157) | TCGA-F5-6814-01 | Colorectum | rectum adenocarcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
DUSP8 | SNV | Missense_Mutation | novel | c.214N>T | p.Pro72Ser | p.P72S | Q13202 | protein_coding | tolerated(0.68) | benign(0.349) | TCGA-A5-A1OF-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
Page: 1 2 3 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |